Quantcast

Latest Entecavir Stories

2014-04-14 11:03:19

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). "Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of...

2011-11-09 14:00:00

⢠96-week study in a population of nucleos(t)ide-naïve patients with chronic hepatitis B (CHB) infection ⢠Data presented at the American Association for the Study of Liver Diseases congress in San Francisco San Francisco, CA (PRWEB) November 09, 2011 Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week results from the BEâLOWâ“ž¢ study, a Phase IIIb clinical trial comparing...

2011-04-27 15:27:00

Virus rebound not linked to antiviral drug resistance; more likely associated with not taking medicine ANN ARBOR, Mich., April 27, 2011 /PRNewswire-USNewswire/ -- A rebound of the Hepatitis B virus is common in patients receiving nucleoside analogs for chronic hepatitis B, according to a study from U-M hepatologists. But nearly 40% of the rebounds or virological breakthroughs (VBTs) were not related to antiviral drug resistance. Details of this retrospective study will be published in...

2011-03-01 07:07:00

PARIS, March 1, 2011 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE:BMY) announced today that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease. BARACLUDE(r) was already approved in Europe in June 2006 for use in adult patients with CHB with compensated liver disease and evidence of active viral replication, persistently elevated serum...

2010-06-17 06:00:00

HAIKOU, China, June 17 /PRNewswire-Asia/ -- Kun Run Biotechnology, Inc. (the "Company" or "Kun Run") (OTC Bulletin Board: KURU), a leading bio-pharmaceutical company in China focusing on manufacturing and sales of peptide-based and small molecule drugs, today announced that they have obtained the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA). Entecavir is an oral antiviral drug used in the treatment of Hepatitis-B infection. It works by...

2009-03-31 08:00:00

FREDERICK, Md., March 31 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of the pyrimidinedione small molecules as antiviral agents at the 13th International Symposium on Viral Hepatitis and Liver Disease meeting held last week in Washington D.C. ImQuest's screening efforts have identified ten pyrimidinediones as inhibitors of HBV replication, with two compounds yielding potent inhibition of HBV replication at sub-micromolar...

2008-11-03 09:00:40

Gilead Sciences, a biopharmaceutical company, has presented two-year data from two Phase III pivotal clinical trials, studies 102 and 103, evaluating the safety and efficacy of once-daily Viread among adult patients with chronic hepatitis B virus infection. These new data show that patients who received Viread for up to 96 weeks experienced sustained suppression of hepatitis B virus (HBV) levels in the blood (91% and 78% for Studies 102 and 103, respectively). The studies also show that all...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.